TIGENIX, S.A.U.;CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS
发明人:
Dirk BÜSCHER,Manuel Angel GONZÁLEZ DE LA PEÑA,Mario Delgado MORA
申请号：
US15581801
公开号：
US20170296593A1
申请日:
2017.04.28
申请国别(地区):
US
年份:
2017
代理人:
摘要：
The present invention provides a population of connective tissue derived cells that respond to interferon-gamma (IFN-γ) by expressing indolamine-2,3-dioxygenase (IDO) for use in preventing, treating or ameliorating one or more symptoms associated with disorders in which modulation of a subject's immune system is beneficial, including, but not limited to, autoimmune diseases, inflammatory disorders, and immunologically mediated diseases including rejection of transplanted organs and tissues.
